RankAlpha logo
Back to Rankings

CSTL

Castle BiosciencesF
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
View Chart
Current thesis
If Castle secures broader reimbursement and demonstrates steady adoption of its diagnostic assays, revenue growth can accelerate and operating leverage could push valuation toward mid-single-digit multiples of near-term revenue, supporting upside to the bull target within 6–12 months.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
If adoption stalls or reimbursement decisions remain unfavorable, revenue will remain constrained, margins compress, and the share price could fall toward the bear target driven by multiple contraction and negative revisions.
Momentum
4
Value
52
Sentiment
15
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.60 · Bull $5.30 · Bear $2.40
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-29 • Model: RankAlpha Sentiment AI
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $48.50
Why
Momentum4 · Δ7d +0.5
Value52 · Δ7d -0.3
Sentiment15 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
4
34% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
-4.4
Value
52
32% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.5
Sentiment
15
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade

Composite grade F. Momentum 3.7 / Value 51.9 / Sentiment 14.7

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$597.8M
Beta
1.06
Shares Out
29.19M
P/E (TTM) · Derived
-24.6
P/S (TTM)
3.31
P/FCF (TTM)
44.86
Rev YoY
-3.2%
EPS YoY
-122.3%
Gross Margin
+79.9%
Op Margin
-10.2%
Net Debt
-$282.7M
Current Ratio
6.47
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology